In addition to multiple metabolic benefits by SGLT2 inhibitors such as improvement of hyperglycemia, obesity, and dyslipidemia that could influence cardiovascular mortality, the present study proposed novel mechanisms by which SGLT2 inhibitors prevented vascular complications in T2DM via modulating PVAT characters. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.